335 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 28626 | Philippe Aftimos | Multiple | Lilly | EMBER | Trial closed for recruitment | A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Therapies for Patients with ER+, HER2-Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers | philippe.aftimos@hubruxelles.be | 1/1b | 1 | ||
| 28736 | Philippe Aftimos | Breast | Lilly | EMBER-2 | Trial closed | EMBER-2 : A phase 1, open-label, preoperative window study evaluating the biological effects of LY3484356 in post-menopausal women with stage I-III estrogen receptor-positive, HER2-negative breast cancer | philippe.aftimos@hubruxelles.be | 1 | 1 | ||
| 29185 | Philippe Aftimos | Breast | Lilly | EMBER-3 / PILOT415 | Trial closed for recruitment | A Randomized, Open-Label, Phase 3 Study of LY3484356 vs Investigator's Choice of Endocrine Therapy, in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy | philippe.aftimos@hubruxelles.be | 3 | 3 | ||
| 29670 | Philippe Aftimos | Breast | Lilly | EMBER-4 - J2J-MC-JZLH | Trial open for recruitment | J2J-MC-JZLH EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence | philippe.aftimos@hubruxelles.be | 3 | 3 | ||
| 22716 | ESR1-mut or ESR1-WT | Philippe Aftimos | Breast | Radius Health, Inc | EMERALD | Trial closed for recruitment | Elacestrant Monotherapy for the Treatment of ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicenter Trial | philippe.aftimos@hubruxelles.be | 3 | 3 | |
| 22820 | N-Ras mutated | Joseph Kerger | Skin | Merck Serono | EMR 200066-007 | Trial closed | A multicentre, open label, randomized Phase II trial of the MEK inhibitor pimasertib or dacarbazine in previously untreated subjects with NRas mutated locally advanced or metastatic malignant cutaneous melanoma | joseph.kerger@hubruxelles.be | 2 | 2 | |
| 29193 | Laura Polastro | Uterus | Seagen | ENGOT-cx12 - SGNTV-003 | Trial closed for recruitment | A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin versus Investigator's Choice Chemotherapy in Second or Third Line Recurrent or Metastatic Cervical Cancer | laura.polastro@hubruxelles.be | 3 | 3 | ||
| 22756 | Male proven invasive breast cancer | Lissandra Dal Lago | Breast | EORTC | EORTC 10085p MALE BREAST | Trial closed for recruitment | EORTC 10085p MALE BREAST Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG, TBCRC and NABCG intergroup study | lissandra.dallago@hubruxelles.be | |||
| 22750 | At least 1 or 2 prior lines of treatment | Yassine Lalami | Thyroïd | EORTC | EORTC 1209-EnTF | Trial closed | A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line therapy | yassine.lalami@hubruxelles.be | 2 | 2 | |
| 22699 | T1 or T2 N0,M0 | Esther Willemse | Head and Neck | EORTC | EORTC 1420-HNCG-ROG | Trial open for recruitment | Phase III study assessing the ?best of? radiotherapy compared to the ?best of? surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0 oropharyngeal carcinoma | esther.willemse@hubruxelles.be | 3 | 3 | |
| 28559 | Tatiana Dragan | EORTC | EORTC 1629 | Trial open for recruitment | Late toxicity and long-term quality of life in head and neck cancer survivors | accueil.cons.radiotherapie@hubruxelles.be | |||||
| 22692 | any line / Lung metastasis | Konstantinos Stathopoulos | Lung | EORTC | EORTC 1658 | Trial closed | Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) | konstantinos.stathopoulos@hubruxelles.be | |||
| 22812 | Availability for long term follow up. Clinically node-negative | Catherine Philippson | Breast | EORTC | EORTC 22085 | Trial open for recruitment | A randomised phase III study of radiation doses and fractionation schedules for ductal carcinoma in situ (DCIS) of the breast | accueil.cons.radiotherapie@hubruxelles.be | |||
| 22763 | Platinium-refractory | Joseph Kerger | Multiple | EORTC | EORTC 55092 | Trial closed | Phase IB-II, open label, multicentre feasibility study of pazopanib in combination with Paclitaxel and Carboplatin in patients with platinumrefractory/ resistant ovarian, fallopian tube or peritoneal carcinoma | joseph.kerger@hubruxelles.be | 1/2 | 1 |